Founded as Implant Innovations Inc. (“3i”) on May 27, 1987 by Dr. Richard Lazzara, a periodontist, and Keith Beaty, an engineer, the company has grown to 1,000 employees with its global headquarters located in Palm Beach Gardens, Florida. BIOMET 3i is recognized for its cutting-edge product innovations in the development of biologically driven implants; winning worldwide acclaim for the microtextured surface of the OSSEOTITE® Implant, which has more than 15 years of documented research. More recently, BIOMET 3i introduced a Bone Bonding® NanoTite™ Surface with a complex architecture at the nano-scale, which produces a mechanical interlocking of the newly formed cement line matrix of bone with the implant surface. BIOMET 3i has also been recognized for its contributions to new dental technologies, such as Digital Dentistry, with the development of its patented BellaTek® Encode® Impression System. At the core of this system is the BellaTek® Encode® Healing Abutment, which incorporates special codes embedded on the occlusal surface that translate the dental implant information needed without the clinician having to make an implant level impression. In addition, the impression of the BellaTek® Encode® Healing Abutment can now be taken with an intraoral scanner allowing for a quicker, more comfortable impression process for the patient.
Superior customer service and supporting continuous learning for dental health care providers have been at the core of the BIOMET 3i Business. This includes the recent launch of the new Institute for Dental Implant and Reconstructive Dentistry (IIRD®), a state-of-the-art learning facility located in Palm Beach Gardens, Florida with affiliated locations in Mexico and Italy that combines leading-edge technology with evidence-based dentistry.
BIOMET 3i has been a leader in the dental industry for 25 years through continuous innovation, education, new market expansion and long standing relationships with global dental schools and societies. BIOMET 3i will continue to focus on treatment solutions that help to optimize dental care for patients, continuing to make implant dentistry a more widely-accepted form of treatment. More specifically, BIOMET 3i will continue to focus on sustainable aesthetics, accelerated treatment times, digitally driven patient and practice management and comprehensive tissue management.
“My dream to better the lives of patients through scientific, evidence-based research has now been fully realized. At BIOMET 3i, our primary goal is to provide clinicians and their patients the simplest, most aesthetic outcomes. I couldn’t be more proud of what we’ve accomplished throughout the past 25 years,” says Dr. Lazzara.